The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience
Gemcitabine and docetaxel demonstrated satisfactory efficacy and acceptable safety in PHE patients; however, clinical trials and large-scale studies are needed to validate these results.
Authors
- Shining Li
- Jie Ma (ORCID: https://orcid.org/0000-0003-0451-7923)
- Xing Zhang (ORCID: https://orcid.org/0000-0002-7883-9258)
- Liyuan Le
- Ruiqing Peng (ORCID: https://orcid.org/0000-0002-5568-103X)
- Qiuzhong Pan (ORCID: https://orcid.org/0000-0002-2145-535X)
- Jing Yang (ORCID: https://orcid.org/0000-0001-6441-709X)
- Bu-Shu Xu (ORCID: https://orcid.org/0009-0001-0889-6169)
- Peng Zhang (ORCID: https://orcid.org/0009-0002-5909-8770)
- Qiyan Cai
- Jiahui Liang
Institutions
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12885-025-14376-6
- Citations
- 2
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China